



# International Journal of Pharmaceutical Research and Development (IJPRD)

Platform for Pharmaceutical Researches & Ideas

www.ijprd.com

## DIRECTLY COMPRESSIBLE FORMS OF ZALTOPROFEN BY SPHERICAL AGGLOMERATION

**E HARI KRISHNA<sup>\*1</sup>,**  
Dr. V. RAM MOHAN GUPTA<sup>2</sup>, S JYOTHI<sup>1</sup>

<sup>1</sup>Dept. of Pharmaceutics, Shadan College of Pharmacy, Peerancheru, Hyderabad-08

<sup>2</sup>Dept. of Pharmaceutics, Pulla Reddy Institute of Pharmacy, Dundigal, Hyderabad.

### ABSTRACT

*The present work deals with the spherical crystallization process by Spherical agglomeration method applied to Zaltoprofen, a novel NSAID drug. The object of present study was to prepare and characterize the spherical agglomeration of water insoluble non-steroidal anti-inflammatory drug. Zaltoprofen spherical agglomerates prepared with sodium alginate, which is hydrophilic polymer by using simple spherical agglomeration technique for enhancing micromeritic properties. The prepared zaltoprofen spherical agglomerates were examined in terms of flow properties, particle size analysis, compression and dissolution behaviour. Physical characters of the crystals were studied for the morphology of crystals using scanning electron microscope (SEM), identification of polymorphism done by x-ray powder diffraction (XPRD) and for thermo dynamic properties using differential scanning calorimetry (DSC). The prepared agglomerates were improved the micromeritic properties, packability, wettability, solubility and compaction behaviour in comparison to pure Zaltoprofen drug.*

**Key words** Direct Compression, Spherical Agglomeration, Zaltoprofen, Spherical Crystallization, bridging liquid, compressibility.

### INTRODUCTION

The conventional tableting method involves first making granules and then compressing into tablets by way of direct (granule) tableting, but the need in recent years for process validation, GMP and automation of production processes has focused

renewal of attention on the direct tableting, which involves few steps.

The direct compression is a modern technique in the tablet manufacturing, many processing steps are limited in direct compression and also wet granulation cannot be used with sensitive drugs<sup>(1)</sup>. Spherical agglomeration is a

### Correspondence to Author



**E HARI KRISHNA**

HOD, Dept. of Pharmaceutics, Shadan College of Pharmacy, Peerancheru, Hyderabad-08

**Email:** elluruharikrishna@gmail.com

modern technique for development of directly compressible drugs where the drug crystals are converted to spherical form to improve flowability, compressibility, packability and to enhance dissolution rate characteristics of poorly water insoluble drug. Also direct tableting of pharmaceutical drugs is desirable to reduce the cost of production<sup>(2)</sup>

Spherical crystallization technique directly transforms the fine particles produced in the crystallization or in the reaction process into a spherical shape<sup>(3)</sup>. Agglomerates exhibit improved secondary characteristic like flowability and compressibility so that direct tableting is possible without further processing. The literature citation reveals that spherical crystals can be made in various ways such as Simple crystallization, Ammonia diffusion system method, Emulsion solvent diffusion method and Neutralization method. Out of these methods available to prepare spherical agglomerates, simple spherical crystallization is very easy, common and faster relative to other methods<sup>(4)</sup> This technique as the name indicates, provides crystalline agglomerates which are spherical in shape, which exhibit excellent micromeritic properties of many drugs such as Fenbrufen<sup>5</sup>, ibuprofen<sup>6</sup>, furosemide<sup>7</sup>, indomethacin<sup>8</sup>, aminophylline<sup>9</sup>, enoxacin<sup>10</sup>, tolbutamide<sup>11</sup>, sulphamethoxazole<sup>12</sup>, phenytoin<sup>13</sup> and norfloxacin<sup>14</sup>

Non-steroidal anti-inflammatory drugs are the most frequently prescribed preparations, Zaltoprofen is a novel NSAID drug exhibit poor flow and compression characteristics and hence it is a suitable candidate for spherical crystallization process to improve flow properties and compressibility. Further, Zaltoprofen shows incomplete and poor oral bioavailability due to low aqueous solubility<sup>(15)</sup>, hence in such case it is a valuable goal to improve therapeutic efficacy.

In the present study, it was planned to prepare spherical crystals of Zaltoprofen to improve the micromeritic properties and dissolution properties using Sodium alginate which is hydrophilic polymer<sup>(16)</sup>.

## MATERIALS:

Zaltoprofen was obtained as a gift sample from M.S Hetero pharmaceutical, Hyderabad. Sodium alginate was obtained from S.D. Fine chemicals Mumbai. Dichloromethane, Acetone and Methanol were supplied from S.D. Fine chemicals Mumbai.

## METHODS:

### PREPARATION OF ZALTOPROFEN SPHERICAL AGGLOMERATES:

Spherical agglomeration of Zaltoprofen was prepared by simple agglomeration technique using three solvent systems. It involved a good solvent, a bad solvent and a bridging liquid. Acetone, dichloromethane and water were selected as good solvent, bridging liquid and poor solvent. These solvents were successfully used in previous studies.

A solution of Zaltoprofen (500 mg) in acetone (3 ml) was added to a solution of Sodium alginate (1-4% w/v) in 100 ml distilled water. The mixture was stirred continuously using digital mechanical stirrer (IKA motors. Mumbai) at 500 rpm, the bridging liquid (Dichloromethane; 0.5 ml) was added drop wise (table 1) and stirring was continued for 30 min. The agglomerates were separated by filtration using whatman filter paper (No. 1) and dried for 24 hours at room temperature.

**Table 1:** Formulation of Zaltoprofen Spherical agglomerates.

Ingredients	F1	F2	F3	F4
Zaltoprofen (mg)	500	500	500	500
Sod. Alg. (%)	1%	2%	3%	4%
Acetone (ml)	3	3	3	3
DCM (ml)	0.5	0.5	0.5	0.5
Water (ml)	100	100	100	100

### EVALUATION OF ZALTOPROFEN SPHERICAL AGGLOMERATES:

#### Shape

The shape of the crystals was observed under optical microscope (10 magnification) attached to computer.

**Crystal density ( $\rho$ )**

It is the density of the actual solid material. This was determined by liquid displacement method by using 25 cc Specific gravity bottle with Toluene as immersion fluid. Three replicate determinations were made and the mean Calculated.

**Bulk density ( $\rho_b$ )**

It is defined as the mass of a powder divided by the bulk volume. This was determined by following the method<sup>(17)</sup>. A sample of 25.0 cc of powder from each batch, which has been previously lightly shaken in a closed container to break any agglomerates formed, was introduced into a 100 ml graduated cylinder. The cylinder was then dropped at 2-second intervals onto a hard wood surface three times from a height of 1 inch. The bulk density was thus obtained by dividing the weight of the sample in grams by the final volume in cc of the sample contained in the cylinder. Three replicate determinations were made and the mean calculated. (Remi Motors, Bombay, India)

**Tap density ( $\rho_t$ )**

It is defined as the mass of a powder divided by the tap volume. A loosely packed volume of 25 cc of the powder from each batch was poured in a measuring cylinder by means of a funnel, after shaking lightly in a closed container. After observing the initial volume, the cylinder was mechanically raised and allowed to fall under its own weight on a hard surface from a height of 2.5 cm at the rate of 120 taps per minute, until no further change in the volume was observed. The tap density was calculated by dividing the weight of the sample in grams by the final volume in c.c. of the sample contained in the cylinder. Three replicate determinations were made and mean calculated.

**% Compressibility (% C)**

Carr derived<sup>(18)</sup> this dimensionless quantity which proves to be useful to the same degree as that of angle of repose values for predicting the flow behaviour. The more compress a material is, the less flowable it will be and the less compressibility, the more flowable. Compressibility indirectly gives an excellent picture of uniformity in Available online on [www.ijprd.com](http://www.ijprd.com)

size and shape, cohesion and moisture content. The formula used was,

$$\% \text{Compressibility} = \frac{\text{Tapped density} - \text{Bulk density}}{\text{Tapped density}} \times 100$$

The computed values for the different batches of crystals were expressed in percent and tabulated.

**Hausner's ratio<sup>(19)</sup>**

Particles with high interparticulate friction or cohesiveness have Hausner ratio greater than 1.6 and % compressibility values higher than 40, whereas powder with Hausner ratio less than 1.2 and % compressibility between 5 to 17 can be classified as free flowing powders. Hausner ratio was calculated using following formula.

$$\text{Hausner's Ratio} = \frac{\text{Tapped density}}{\text{Bulk density}}$$

**Porosity**

The state of packing of a powder is described by its porosity, which is defined as the ratio of the void volume to the bulk volume of the packing.

$$\text{Porosity} = \frac{\text{Bulk volume} - \text{Tapped volume}}{\text{Bulk volume}} \times 100$$

Porosity is frequently expressed in percent. Porosity values were computed for all batches using the formula.

**Angle of repose ( $\phi$ )**

Angle of repose was determined for all the batches as an index of flow behaviour using basically, the method suggested by Philpel<sup>20</sup>. The height H and mean radius r measured from five different directions were used to calculate the angle of repose, using the formula,

$$\text{Angle of Repose } (\phi) = \tan^{-1} H / r$$

Five replicate determinations were made in similar conditions of relative humidity and mean angle of repose values were calculated.

**Scanning electron microscopy**

The surface morphology of the agglomerates was assessed by scanning electron microscopy (Lexica stereo Scan S-3700; Cambridge, UK).

**Drug content determination**

The drug content of the crystals was determined by dissolving agglomerates containing 80 mg of zaltoprofen in 100 ml of methanol followed by measuring the absorbance of appropriately diluted solution spectrophotometrically. (Pharmaspec UV-1700, UV-Visible Spectrophotometer, Shimadzu, Tokyo, Japan) at 340 nm.

**Invitro dissolution studies**

The invitro dissolution studies were carried out using 8 station USP XXIII dissolution testing apparatus (Electrolab, Mumbai, India). The dissolution medium used was 900 ml, mixture of phosphate buffer solution pH 6.8 and water (1:1) used as dissolution medium<sup>(21)</sup>. The agglomerates containing 80 mg of zaltoprofen were weighed and then introduced into the dissolution medium. The medium was stirred at 50 rpm using paddle at  $37 \pm 0.5$  °C. The samples were collected, filtered

through whatman filter paper (0.45um) and analyzed spectrophotometrically at 340 nm.

**RESULTS AND DISCUSSION:**

Spherical Agglomerates of Zaltoprofen were prepared by simple spherical agglomeration, which involves a good solvent, a poor solvent and bridging liquid. From the solubility data of zaltoprofen, the solvents are selected since zaltoprofen is highly soluble in acetone, insoluble in water, acetone selected as good solvent, water as poor solvent and dichloromethane as bridging liquid as the dichloromethane has good wettability with the drug and immiscible with the water. The percentage of drug content of the prepared agglomerates showed between 93% to 98% and it was highest with F2 i.e.  $98.28 \pm 2.18$  shown in Table 2.

**Table 2:** Percentage drug content of Zaltoprofen Spherical Agglomerates.

Spherical crystals	Drug content (%)
Sodium Alginate (1%)	$97.18 \pm 1.58$
Sodium Alginate (2%)	$98.28 \pm 2.18$
Sodium Alginate (3%)	$94.82 \pm 1.81$
Sodium Alginate (4%)	$93.61 \pm 2.26$
ZALTOPROFEN(pure)	$100.00 \pm 0.00$

**Micromeritic properties:****Flow properties, Porosity and Density:**

The flow properties of zaltoprofen spherical agglomerates were studied in term of Hausner's ratio, Carr's Index and Angle of repose, which were mentioned in table 3. The Carr's index significantly reduced by the spherical agglomerates (less than 19.0) than that of pure drug (42.0) which indicates significant increase in flow rate of the agglomerates. Hausner's ratio of agglomerates was less than 1.2, which indicates improved flowability of agglomerates. Angle of repose of spherical agglomerates falls between 30 to 34, among the four formulations F2 had reduced angle of repose

indicates better flow properties, this may be the significant reduction in interparticle friction because of the good spherical shape and larger size of the spherical agglomerates. The percentage of the porosity of agglomerated crystals showed significantly higher as compared to the raw crystals of zaltoprofen, increased porosity improves the wettability and dissolution rate at little extent. From the bulk, granular, and true density of the agglomerated crystals, the results indicated that all densities of the agglomerated crystals showed decrease value because of the increased in volume and the total porosity of agglomerated crystals (Table 3).

**Table 3:** Micromeritic properties of zaltoprofen spherical crystals prepared in the presence of different concentrations of Sodium alginate and pure drug




Spherical Crystals	LBD (g/ml)	TBD (g/ml)	Carr s Index	Hausner's ratio (%)	Angle of Repose (g/ml)	True Density	Porosity (%)	Particle size
F1	0.32± 0.01*	0.42± 0.01*	19.0± 1.32*	1.25± 0.02*	31.69 ± 1.85	1.29 ± 0.17	66.3 ± 1.96	298.53 ± 11.23
F2	0.40± 0.02*	0.45 ± 0.01*	11.11± 1.62*	1.125 ± 0.03*	24.77 ± 1.98	1.287 ± 0.12	65.03 ± 2.31	530.88 ± 19.63
F3	0.40± 0.02*	0.42± 0.01*	4.76± 1.82*	1.05 ± 0.02*	34.42 ± 2.01	1.24 ± 0.09	67.74 ± 2.90	1333.52 ± 28.33
F4	0.35 ± 0.01*	0.40 ± 0.02*	10.10± 1.05*	1.10 ± 0.02*	30.12 ± 1.32	1.36 ± 0.10	70.7 ± 2.12	1888 ± 25.36
PURE Drug	0.30 ± 0.01	0.52 ± 0.02	42.00 ± 2.36	1.69 ± 0.03	42.61± 1.99	1.55± 0.46	55.50± 2.21	85.55 ± 10.25

**Scanning electron microscopy:**

The results of surface morphology studies were shown in SEM Fig 1. The parent zaltoprofen crystals were in the form of fine needles, which is in confirmation with the earlier report. This long-

**Fig. 1(a)** SEM micrograph pure zaltoprofen, 1(b),(c) SEM micrographs of Spherical agglomerates F2.

needle form of zaltoprofen leads to very poor flow and compressional difficulties. The prepared agglomerates were spherical to larger extent and remaining was irregular in shape with smooth surface, which enabled them flow very easily.

**Fig 1(a)****Fig 1(b)****Fig 1(c)****FTIR Spectroscopy:**

IR spectroscopy and DSC studied the possible interaction between the drug and the carrier. The interaction often leads to identifiable changes in the IR profile and melting point of drug. The principal IR peaks of pure zaltoprofen and IR

peaks of spherical agglomerates were shown in Table 4, Figure 2 (a), (b). No considerable changes were observed in the IR peaks of crystals when compared to pure zaltoprofen. These observations indicate the absence of well-defined interaction

between zaltoprofen, sodium alginate and other additives used in the crystals.

**Fig. 2** IR spectra of a) Zaltoprofen b) Spherical agglomerates F2.




Figure 2 (a)




Figure 2 (b)

**Table 4:** FTIR Wave numbers of pure drug and sodium alginate spherical crystals

Samples	Major peaks (Wave numbers), cm <sup>-1</sup>
Pure Zaltoprofen	1705.08, 1672.58, 1588.29, 1458.11, 1014.06, 603..34
Spherical Crystals (2% Sodium Alginate)	1704.79, 1672.52, 1588.35, 1458.10, 1040.43, 603.43

**Differential scanning calorimetric studies:**

The DSC thermograms of pure zaltoprofen and its crystal forms were shown in Fig. 3 (a), (b). Pure zaltoprofen showed a sharp endotherm at 140.81 °C corresponding to its melting point. Zaltoprofen spherical crystals showed sharp endotherm at 140.70 °C . There was negligible change in the melting endotherms of the spherical

crystals compared to pure drug. This observation further supports the IR spectroscopy results, which indicated the absence of any interactions between drug, Sodium alginate and additives used in the preparation. However, there was a decrease, although very little, in the melting point of drug in spherical crystals compared to that of pure zaltoprofen.

**Fig. 3** DSC Patterns of a) Zaltoprofen b) Spherical agglomerate F2




Fig 3(a)





Fig 3(a)

FTIR spectra and DSC studies of agglomerates showed that, the drug was stable in the prepared formulations indicating the absence of interaction between zaltoprofen and hydrophilic polymers.

#### X-Ray diffraction studies:

Comparison of powder X-ray diffraction spectra of zaltoprofen and spherical agglomerates indicate considerable decrease in crystallinity of spherical agglomerates. After the recrystallization, no polymorphic phenomenon was detected, as all

**Fig. 4** X-Ray diffraction Patterns of a) Zaltoprofen b) Spherical agglomerate F2




**Fig. 4(a)**

#### Dissolution studies:


The results of in vitro dissolution studies are shown in Figure 5. Pure sodium alginate exhibited less release at the end of 120 min. whereas spherical crystals improved the dissolution rate of sodium alginate. The drug release after 120 minutes from the spherical crystals prepared in the presence of 1 % to 4 % w/v sodium alginate were 83.1, 99.3, 88.5, 73.2%% respectively, which indicates that the spherical crystals prepared with

powder X-ray diffraction patterns of primary crystals consisting of agglomerates were consistent with the pattern of original crystals. The decrease in crystallinity of the drug indicates increase in amorphous nature the drug, which may increase in the solubility of the drug. After the recrystallization, no polymorphic phenomenon is detected using X-ray diffractometer as all powder X-ray diffraction patterns of the primary crystals consisting of agglomerates were consistent with the pattern of original crystals Fig 4(a),(b).



**Fig.4(b)**

2 % w/v sodium alginate exhibited maximum drug release ( $99.3 \pm 0.29$  %) and the drug release was not increased with spherical crystals prepared with higher concentration of sodium alginate i.e., 3% and 4 % w/v which may be attributed to the fact that the dissolution rate may be retarded as the size of the spherical crystals was more in case of 3 % w/v and 4 % w/v spherical crystals of sodium alginate.

**Figure 5:** Dissolution profiles of pure drug and agglomerates prepared in sodium alginate (1% to 4% w/v)**CONCLUSION:**

The spherically agglomerated crystals of zaltoprofen were successfully prepared for direct tableting by the spherical agglomeration technique. The micromeritic properties of agglomerates such as flowability, packability and compactibility were dramatically improved, resulting in successful direct tableting. The agglomerates have shown improved invitro drug release performance comparable with untreated zaltoprofen. The main factor in the improvement of flowability and packability was due to their spherical shapes and smooth surfaces. Therefore, from the above it can be concluded that spherical crystallization is a tool of particle engineering, which can transform the poorly flowable drug powder into spherical crystals, those are best suited for direct compression. The conversion of poorly flowable powder into spherical agglomerates enhances the speed of tableting because of elimination of most of steps, which required in the wet granulation and in dry granulation process.

**REFERENCES**

1. Ali Nikhodchi, Davood and Hasanzadeh An improvement of physicomechanical properties

of carbamazepine crystal, Iranian journal of Pharmaceutical research (2007),6(2) 83-93

2. R.F.Shangraw, *compressed tablets by direct compression*, in *Pharmaceutical Dosage Forms: Tablets*, vol.1 (Ed.H.A.Lieberman, L.Lachman, J.B.Schwartz) Marcel Dekkar, New york, 1989, pp. 195-246
3. Kawashima Y., Okumaura M. and Takenaka H. (1982). *Science*, 216:1128
4. Chourasia M.K., Nitin K. Jain., S. Jain, Jain N.K., and Jain S.K : Preparation and characterization of Agglomerates of Flurbiprofen by Spherical Crystallization technique, *Ind. Journal of Pharm. Sciences*, May-June 2003,287-290
5. Martino D.P., Barthelemy C., Piva F., Joiris E., Palmieri G.F. and Martelli S. (1991). *Ind. Pharm.*, 25: 1073.
6. Jbilou M., Ettabia A., Guyot-Hermann A.M. and Guyot J. C. (1999). *Drug develop. Ind. Pharm.*, 25: 297.
7. Akbuga J. (1991). *Int. J. Pharm.*, 56: 193.
8. Kawashima Y., Lin S. Y. and Ogawa M. (1985). *J. Pharm. Sci.*, 74:1152.
9. Kawashima Y., Aoki S. and Takenaka H. (1984). *J. Pharm. Sci.*, 73, 1407.
10. Kawashima Y., Okumura M. and Takenaka H. (1984). *J. Pharm. Sci.*, 73: 1535.

11. Sano T. Kuriki and Handa T. (1987). J. Pharm. Sci., 76: 471.
12. Kawashima Y., Ohno H. and Takenaka H. (1981). J. Pharma. Sci., 70: 913.
13. Kawashima Y., Handa T., Takenchi H. and Okumaram H. (1986). Chem. Pharm. Bull., 34: 3376.
14. Puechagut H.G., Bianchotti J. and Chaile C.A. (1998). J. Pharm. Sci., 87: 519.
15. The Japanesse Pharmacopoeia, 15<sup>th</sup> edition, 1242-1243.
16. Hand book of Pharmaceutical Excipients, Raymond C Rowe, Paul J, Sheskey and Sian C owen, 1736-1743
17. Martin A; 2002. Micromeritics.In:Physical Pharmacy:Physical chemical principles in the pharmaceutical sciences ,4<sup>th</sup> Edition;Lippincott Williams &Wilkins,Baltimore, Maryland-USA.
18. Carr R.L, Chem. Engr., 72, 163, 72 and 69, (1965).
19. Wells J, 2002, Pharmaceutical preformulation: The physico chemical properties of drug substances. In : Pharmaceutics – The science of dosage form design. M. E. Aulton (Ed), 2<sup>nd</sup> Ed, Churchill Livingstone. London: P.P 113-138.
20. Philpel, N., J. Pharm. Pharmacol., 16, 705, (1964).
21. The Japanesse Pharmacopoeia, 15<sup>th</sup> edition, 1243-1244.

\*\*\*\*\*